Mr. Justin Hanka reports

MINDBIO TO REVOLUTIONISE DRUG AND ALCOHOL TESTING IN THE MINING INDUSTRY USING AI VOICE-BASED DRUG & ALCOHOL DETECTION SOLUTION

Mindbio Therapeutics Corp.'s chief executive officer, Justin Hanka, has met with mining and health executives in South America, to discuss potential deployment of the company's technology into the mining industry.

The company has been showcasing its technology as an enterprise solution and has led to interest from mining and health officials in South America, who are interested in deploying the company's intoxication technology "at the gate" as a first line screen for multiple substances such as alcohol, hallucinogens, amphetamines, cocaine and cannabis.

Mindbio is investing heavily in developing its proprietary drug and alcohol prediction technologies for use at scale in enterprise environments. The platform technology in development has wide applications particularly in employment situations, such as in the mining industry where broad screening for drug and alcohol intoxication in mining workers in South America is government mandated. Alcohol and drug testing in the mining industry at scale is currently slow, expensive, time consuming and personally invasive (that is, involves collecting saliva, urine or blood samples plus breath tests). Drug and alcohol testing is an essential aspect of ensuring the health and safety of workers and preventing accidents that can cause massive delays and cost blowouts from a single avoidable accident. One accident can cost a mining company hundreds of millions in delayed production, site boycotts by unions, insurance and medical expenses.

National work force studies in Chile alone show that alcohol consumption among mining workers exceeds 75 per cent and the proportion of problem drinkers is above 40 per cent with drug use estimated in 9 per cent of the more than 200,000 mining workers in the country (ACHS, 2012: SENDA, 2024). And internationally more than 20 to 25 per cent of all occupational accidents are directly or indirectly linked to substance use (International Labour Organization 1996, 2022: Gomez et al., 2002). This translates to tens of thousands of preventable workplace incidents related to drug and alcohol intoxication.

The company's core technology can reliably predict intoxication with hallucinogens and alcohol by analyzing voice. The company plans to expand its algorithms to be able to detect other prohibited drugs that are difficult to detect particularly at scale and volume and require specialized equipment, with Mindbio's solution provided by a simple analysis of the voice over its proprietary AI platform.

The company's CEO, Justin Hanka, said, "We are delighted by the commercial interest in our core technology by the mining industry and will work with our counterparts in South America to develop and deploy an appropriate solution for the region which represents a massive opportunity for the company to disrupt drug and alcohol testing processes in the mining industry globally."

About Mindbio Therapeutics Corp.

Mindbio Therapeutics is a biotechnology company headquartered in Vancouver, B.C., that for several years has been conducting drug and alcohol research and has created health prediction technologies using AI (artificial intelligence) and machine learning. The company has expertise in using speech analytics as a prediction tool for drug and alcohol intoxication and has created a world first voice and AI-powered prediction model for drug and alcohol intoxication for use in consumer and enterprise situations. The company is developing a comprehensive enterprise platform using voice and powered by AI for use in detecting drug and alcohol intoxication in workplaces, law enforcement, mental health and telehealth.

We seek Safe Harbor.